Pitfall in nephrology: Contrast nephropathy has to be differentiated from renal damage due to atheroembolic disease

Journal of Nephrology

Volumn 25, Issue 3, 2012, Pages 282-289

  Stratta, Piero ^a   Bozzola, Cristina ^b   Quaglia, Marco ^a  

^a Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Atheroembolic disease; Contrast induced nephropathy; Iodinated contrast media; Renal cholesterol embolism

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CONTRAST MEDIUM; CREATININE; DIURETIC AGENT; VASODILATOR AGENT;

ASYMPTOMATIC DISEASE; ATHEROEMBOLIC DISEASE; BLEEDING; CHOLESTEROL EMBOLISM; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DRUG INFUSION; HEMODYNAMICS; HUMAN; HYDRATION; HYPOTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PERFUSION; KIDNEY TUBULE DAMAGE; NEPHROTOXICITY; PROGNOSIS; PROPHYLAXIS; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; VASCULAR DISEASE;

CONTRAST MEDIA; EMBOLISM, CHOLESTEROL; HUMANS; KIDNEY; KIDNEY DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 84863311583     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000093     Document Type: Review

References (60)

1. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419-1428.
2. Solomon R. Contrast-induced acute kidney injury (CIAKI). Radiol Clin North Am. 2009;47(5):783-788, v.
3. Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short-and long-term implications. Semin Nephrol. 2011;31(3):300-309.
4. Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med. 2006;34(8): 2060-2068.
5. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol. 2009;22(3):333-351.
6. Jasuja D, Mor MK, Hartwig KC, Palevsky PM, Fine MJ, Weisbord SD. Provider knowledge of contrast-induced acute kidney injury. Am J Med Sci. 2009;338(4):280-286.
7. Palevsky PM. Defining contrast-induced nephropathy. Clin J Am Soc Nephrol. 2009;4(7):1151-1153.
8. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006;239(2):392-397.
9. Josephson SA, Dillon WP, Smith WS. Incidence of contrast nephropathy from cerebral CT angiography and CT perfusion imaging. Neurology. 2005;64(10):1805-1806.
10. Asif A, Cherla G, Merrill D, et al. Venous mapping using venography and the risk of radiocontrast-induced nephropathy. Semin Dial. 2005;18(3):239-242.
11. Ng CS, Shaw AD, Bell CS, Samuels JA. Effect of IV contrast medium on renal function in oncologic patients undergoing CT in ICU. AJR Am J Roentgenol. 2010;195(2):414-422.
12. Langner S, Stumpe S, Kirsch M, Petrik M, Hosten N. No increased risk for contrast-induced nephropathy after multiple CT perfusion studies of the brain with a nonionic, dimeric, iso-osmolal contrast medium. AJNR Am J Neuroradiol. 2008; 29(8):1525-1529.
13. Pahade JK, LeBedis CA, Raptopoulos VD, et al. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol. 2011;196(5):1094-1101.
14. Lufft V, Hoogestraat-Lufft L, Fels LM, et al. Contrast media nephropathy: intravenous CT angiography versus intraarterial digital subtraction angiography in renal artery stenosis: a prospective randomized trial. Am J Kidney Dis. 2002; 40(2):236-242.
15. Katzberg RW, Newhouse JH. Intravenous contrast mediuminduced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010;256(1):21-28.
16. Crudu V, Blankenship J, Berger P, Scott T, Skelding K. Complications related to access site after percutaneous coronary interventions: are the adverse events underreported? Catheter Cardiovasc Interv. 2011;77(5):643-647.
17. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A. L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart. 2008;94(8):1019-1025.
18. Vuurmans T, Byrne J, Fretz E, et al. Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries). Heart. 2010;96(19):1538-1542.
19. Wu C, Liao D, Dyer AM, Chen H, Gilchrist IC. The transradial approach is associated with lower risk of adverse outcomes following percutaneous coronary intervention: a single-center experience. J Invasive Cardiol. 2011;23(3):88-92.
20. Jolly SS, Niemelä K, Xavier D, et al. Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes. Am Heart J. 2011;161(2):254-260, e1-e4.
21. Weisz G, Leon MB. Interventional cardiology: hand me your radial artery to protect your kidney. Nat Rev Cardiol. 2010; 7(12):674-675.
22. Brueck M, Bandorski D, Kramer W, Wieczorek M, Höltgen R, Tillmanns H. A randomized comparison of transradial versus transfemoral approach for coronary angiography and angioplasty. JACC Cardiovasc Interv. 2009;2(11):1047-1054.
23. Santas E, Bodí V, Sanchis J, et al. The left radial approach in daily practice: a randomized study comparing femoral and right and left radial approaches. Rev Esp Cardiol. 2009; 62(5):482-490.
24. Chodór P, Krupa H, Kurek T, et al. RADIal versus femoral approach for percutaneous coronary interventions in patients with Acute Myocardial Infarction (RADIAMI): a prospective, randomized, single-center clinical trial. Cardiol J. 2009;16(4):332-340.
25. Eichhöfer J, Horlick E, Ivanov J, et al. Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: a large single-center experience. Am Heart J. 2008; 156(5):864-870.
26. Rao SV, Ou FS, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008;1(4):379-386.
27. Jaffe R, Hong T, Sharieff W, et al. Comparison of radial versus femoral approach for percutaneous coronary interventions in octogenarians. Catheter Cardiovasc Interv. 2007;69(6):815-820.
28. King A. Interventional cardiology: radial artery access-a RIVAL to the femoral approach. Nat Rev Cardiol. 2011;8(6):302.
29. de Bie MK, van Rees JB, Herzog CA, Rabelink TJ, Schalij MJ, Jukema JW. How to reduce the incidence of contrast induced acute kidney injury after cardiac invasive procedures, a review and practical recommendations. Curr Med Res Opin. 2011;27(7):1347-1357.
30. La Manna G, Pancaldi LG, Capecchi A, et al. Risk for contrast nephropathy in patients undergoing coronarography. Artif Organs. 2010;34(6):E193-E199.
31. Solomon RJ, Natarajan MK, Doucet S, et al; Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115(25):3189-3196.
32. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol. 2008;191(2):376-382.
33. Katzberg RW, Lamba R. Contrast-induced nephropathy after intravenous administration: fact or fiction? Radiol Clin North Am. 2009;47(5):789-800, v.
34. Canavese C, Morra F, Morellini V, et al. How can we be sure that renal dysfunction after coronary angiography is just explained by contrast nephropathy? Kidney Int. 2004;66(4):1717 [author reply: 1717-1718].
35. Faria B, Vidinha J, Pêgo C, et al. Atheroembolic renal disease with rapid progression and fatal outcome. Clin Exp Nephrol. 2011;15(1):159-163.
36. James MT, Ghali WA, Tonelli M, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010;78(8):803-809.
37. Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol. 2009;4(7):1162-1169.
38. Weisbord SD, Palevsky PM. Acute kidney injury: kidney injury after contrast media: marker or mediator? Nat Rev Nephrol. 2010;6(11):634-636.
39. Scolari F, Ravani P, Gaggi R et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation. 2007;116(3):298-304.
40. Machino-Ohtsuka T, Seo Y, Ishizu T, et al. Combined assessment of carotid vulnerable plaque, renal insufficiency, eosinophilia, and hs-CRP for predicting risky aortic plaque of cholesterol crystal embolism. Circ J. 2010;74(1):51-58.
41. Paraskevas KI, Koutsias S, Mikhailidis DP, Giannoukas AD. Cholesterol crystal embolization: a possible complication of peripheral endovascular interventions. J Endovasc Ther. 2008; 15(5):614-625.
42. Olin JW. Atheroembolic renal disease: underdiagnosed and misunderstood. Catheter Cardiovasc Interv. 2007;70(6): 789-790.
43. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast mediuminduced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038-1046.
44. Hogan SE, L'Allier P, Chetcuti S, et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J. 2008;156(3):414-421.
45. From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008;3(1):10-18.
46. Brown JR, Block CA, Malenka DJ, O'Connor GT, Schoolwerth AC, Thompson CA. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv. 2009; 2(11):1116-1124.
47. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med. 2009;7:23.
48. Trivedi H, Nadella R, Szabo A. Hydration with sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Clin Nephrol. 2010;74(4):288-296.
49. Kunadian V, Zaman A, Spyridopoulos I, Qiu W. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials. Eur J Radiol. 2011;79(1):48-55.
50. Ferrario F, Barone MT, Landoni G, et al. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy: a randomized controlled study. Nephrol Dial Transplant. 2009;24(10): 3103-3107.
51. Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F. N-Acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials. 2009;10:45.
52. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low-or isoosmolar contrast agent exposure. AJR Am J Roentgenol. 2008;191(1):151-157.
53. Feldkamp T, Baumgart D, Elsner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol. 2006;66(5):322-330.
54. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrastinduced nephropathy. Ann Intern Med. 2008;148(4):284-294.
55. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Statins and contrast-induced nephropathy: issues requiring further investigation. Int J Cardiol. 2011;151(3):364.
56. Laville M, Juillard L. Contrast-induced acute kidney injury: how should at-risk patients be identified and managed? J Nephrol. 2010;23(4):387-398.
57. Kagan A, Sheikh-Hamad D. Contrast-induced kidney injury: focus on modifiable risk factors and prophylactic strategies. Clin Cardiol. 2010;33(2):62-66.
58. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol. 2008;49(6):646-657.
59. Solomon R, Deray G; Consensus Panel for CIN. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl. 2006;69 (100):S51-S53.
60. Stratta P, Quaglia M, Airoldi A. Structure-function relationship of iodinated contrast media and risk of nephrotoxicity. Curr Med Chem. 2011 Dec 29. [Epub ahead of print].